Whitehawk (WHWK) CSO David Dornan Receives Award

What Happened
David Dornan, Chief Scientific Officer of Whitehawk Therapeutics (WHWK), was granted two awards of 85,887 shares each (171,774 total) on September 15, 2026. Each award is reported as a derivative grant at $0.00 (no cash paid). These awards are equity grants (restricted stock units / contingent rights to shares), not open-market purchases or sales.

Key Details

• Transaction date: September 15, 2026; Form 4 amended filed September 18, 2026 to correct prior disclosure.
• Grant details: two awards of 85,887 shares each (total 171,774); reported price $0.00; transaction code A = Award/Grant (derivative).
• Vesting: filing includes two vesting descriptions. A corrected footnote states 100% of the award vests on the one-year anniversary of the Vesting Commencement Date (Vesting Commencement Date = Sept 15, 2026). Another footnote describes a standard 4‑year schedule (25% after one year then monthly) — the amended filing clarifies the one‑year cliff applies.
• RSU note: each RSU represents a contingent right to one share of common stock; shares are received only upon vesting.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Filing status: this is an amended Form 4 correcting the previously reported vesting schedule; the amendment does not show any immediate sale or cashless exercise.

Context
These are equity compensation awards, so no cash changed hands on grant. Because the amended filing clarifies vesting (100% cliff at one year per the correction), the awards will only convert to shares if Dornan remains a service provider through the vesting date. This filing corrects prior disclosure; it does not by itself indicate buying or selling intent.